Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM, Ardizzoni A. Musolino A, et al. Among authors: bisagni g. J Clin Oncol. 2008 Apr 10;26(11):1789-96. doi: 10.1200/JCO.2007.14.8957. Epub 2008 Mar 17. J Clin Oncol. 2008. PMID: 18347005
Author Correction: Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial.
Dieci MV, Bisagni G, Bartolini S, Frassoldati A, Vicini R, Balduzzi S, D'amico R, Conte P, Guarneri V. Dieci MV, et al. Among authors: bisagni g. NPJ Breast Cancer. 2023 Apr 12;9(1):24. doi: 10.1038/s41523-023-00532-3. NPJ Breast Cancer. 2023. PMID: 37045875 Free PMC article. No abstract available.
Low-dose aminoglutethimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research.
Cocconi G, Bisagni G, Ceci G, Bacchi M, Boni C, Brugia M, Carpi A, Di Costanzo F, Franciosi V, Gori S, et al. Cocconi G, et al. Among authors: bisagni g. J Clin Oncol. 1992 Jun;10(6):984-9. doi: 10.1200/JCO.1992.10.6.984. J Clin Oncol. 1992. PMID: 1588379 Clinical Trial.
Cisplatin and etoposide in advanced colorectal carcinoma.
Passalacqua R, Bisagni G, Cocconi G, Boni C, Di Blasio B, Ceci G. Passalacqua R, et al. Among authors: bisagni g. Ann Oncol. 1991 Oct;2(9):687-8. doi: 10.1093/oxfordjournals.annonc.a058050. Ann Oncol. 1991. PMID: 1742225 Free article.
A comparison of continuation versus late intensification followed by discontinuation of chemotherapy in advanced breast cancer. A prospective randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).
Cocconi G, Bisagni G, Bacchi M, Buzzi F, Canaletti R, Carpi A, Ceci G, Colozza A, De Lisi V, Lottici R, et al. Cocconi G, et al. Among authors: bisagni g. Ann Oncol. 1990;1(1):36-44. doi: 10.1093/oxfordjournals.annonc.a057671. Ann Oncol. 1990. PMID: 2078484 Free article. Clinical Trial.
Estrogen receptors and breast cancer: a new approach to the cut-off problem.
Bozzetti C, Passalacqua R, Bisagni G, Bella M, Naldi N, Guazzi A, Benecchi M, Cocconi G. Bozzetti C, et al. Among authors: bisagni g. Int J Biol Markers. 1988 Jan-Mar;3(1):68. doi: 10.1177/172460088800300117. Int J Biol Markers. 1988. PMID: 3249048 No abstract available.
115 results